Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35

Benzinga · 2d ago
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.